Illustrative image – not actual.Biocon is planning to ramp up investment in its small and complex drug molecules vertical over coming years.
For this augmentation proceeds will be utilised from a proposed initial public offering of its biologics operations.
The company plans to invest a part of the funds it collects from private equity (PE) firms and the IPO of subsidiary Biocon Biologics India back into the small molecules operations.
